BUSRA GUREL

Dr. BUSRA GUREL

Sabancı University, Istanbul, İstanbul, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2017 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
MBMustafa Caglar Beker
Mustafa Caglar Beker
BCBerrak Caglayan
Berrak Caglayan
EYEsra Yalcin
Esra Yalcin
ACAhmet Burak Caglayan
Ahmet Burak Caglayan
STSeyma Turkseven
Seyma Turkseven
EKErtugrul Kilic
Ertugrul Kilic

1 April 2021 in Analytica Chimica Acta
Verified
Journal Article
Closed access
MYMeral Yüce
Meral Yüce
FSFatma Sert
Fatma Sert
MTMilad Torabfam
Milad Torabfam
APAyhan Parlar
Ayhan Parlar
BGBUSRA GUREL
BUSRA GUREL
YÇYılmaz Çapan
Yılmaz Çapan

17 January 2019 in Journal of Periodontology
Verified
Journal Article
Closed access
PDF file
Esra GuzeldemirEsra Guzeldemir
Esra Guzeldemir
BABegum Alkan
Begum Alkan
DSDeniz Sunnetci‐Akkoyunlu
Deniz Sunnetci‐Akkoyunlu
BGBUSRA GUREL
BUSRA GUREL
VBV. Merve Balta
V. Merve Balta
HSHakan Savli
Hakan Savli

23 January 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
BGBUSRA GUREL
BUSRA GUREL
MCMehmet Cansev
Mehmet Cansev
CSCansu Sevinc
Cansu Sevinc
SKSeda Kelestemur
Seda Kelestemur
BOBusra Ocalan
Busra Ocalan
ABAhmet Baykal
Ahmet Baykal
In recent years, an increasing number of research papers revealed that the compositional and volumetric alterations in the extracellular matrix are the consequences of aging and may be related to Alzheimer’s disease (AD). In this study, we aimed to demonstrate the alterations in hippocampal extracellular fluid proteins in vivo using the 5XFAD mouse model. Samples were obtained from hippocampi of 5XFAD mice ( n = 6) and their non-transgenic littermates by intracerebral push-pull perfusion technique at 3 months of age, representing the pre-pathological stage of the AD. Proteins in the hippocampal perfusates were analyzed by Ultra Performance Liquid Chromatography-Electrospray Ionization Quadrupole Time-of-Flight Mass Spectrometry (UPLC-ESI-qTOF-MS/MS). 178 proteins were identified and 19 proteins of them were found to be statistically significantly altered ( p≤0.05, fold change ≥40%, unique peptide count ≥3) in the hippocampal CA1 extracellular fluid of the 5XFAD mouse model. Ingenuity pathway analysis of the protein expression results identified IL6 as an upstream regulator. The upregulation of IL6 was validated by immunohistochemical staining of the hippocampus and cortex of the 5XFAD mice prior to Aβ plaque formation. Furthermore, the iron level in the hippocampus was measured by inductively coupled plasma-mass spectrometry as IL6 is mentioned in several studies to take part in iron homeostasis and inflammation and found to be increased in 5XFAD mice hippocampus. Alterations in extracellular matrix proteins in addition to increasing amount of hippocampal IL6 and iron in the early stages of AD may reveal inflammation-mediated iron dyshomeostasis in the early stages of neurodegeneration.

4 September 2019 in Current Alzheimer Research
Verified
Journal Article
Closed access
BGBUSRA GUREL
BUSRA GUREL
MCMehmet Cansev
Mehmet Cansev
CKCansu Koc
Cansu Koc
BOBusra Ocalan
Busra Ocalan
ACAysen Cakir
Aysen Cakir
ABAhmet Baykal
Ahmet Baykal
Background: CA1 subregion of the hippocampal formation is one of the primarily affected structures in AD, yet not much is known about proteome alterations in the extracellular milieu of this region. Objective: In this study, we aimed to identify the protein expression alterations throughout the pre-pathological, progression and pathological stages of AD mouse model. Method: The CA1 region perfusates were collected by in-vivo intracerebral push-pull perfusion from transgenic 5XFAD mice and their non-transgenic littermates at 3, 6 and 12 wereβmonths of age. Morris water maze test and immunohistochemistry staining of A performed to determine the stages of the disease in this mouse model. The protein expression differences were analyzed by label-free shotgun proteomics analysis. Results: A total of 251, 213 and 238 proteins were identified in samples obtained from CA1 regions of mice at 3, 6 and 12 months of age, respectively. Of these, 68, 41 and 33 proteins showed statistical significance. Pathway analysis based on the unique and common proteins within the groups revealed that several pathways are dysregulated during different stages of AD. The alterations in glucose and lipid metabolisms respectively in pre-pathologic and progression stages of the disease, lead to imbalances in ROS production via diminished SOD level and impairment of neuronal integrity. Conclusion: We conclude that CA1 region-specific proteomic analysis of hippocampal degeneration may be useful in identifying the earliest as well as progressional changes that are associated with Alzheimer’s disease.

31 May 2022 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
BGBUSRA GUREL
BUSRA GUREL
EÇEda Çapkın
Eda Çapkın
APAyhan Parlar
Ayhan Parlar
AOAylin Ozkan
Aylin Ozkan
MÇMeltem Çorbacıoğlu
Meltem Çorbacıoğlu
MYMeral Yüce
Meral Yüce
Bevacizumab is a humanized therapeutic monoclonal antibody used to reduce angiogenesis, a hallmark of cancer, by binding to VEGF-A. Many pharmaceutical companies have developed biosimilars of Bevacizumab in the last decade. The official reports provided by the FDA and EMA summarize the analytical performance of biosimilars as compared to the originators without giving detailed analytical procedures. In the current study, several key methods were optimized and reported for analytical and functional comparison of bevacizumab originators (Avastin, Altuzan) and approved commercial biosimilars (Zirabev and Mvasi). This case study presents a comparative analysis of a set of biosimilars under optimized analytical conditions for the first time in the literature. The chemical structure of all products was analyzed at intact protein and peptide levels by high-resolution mass spectrometry; the major glycoforms and posttranslational modifications, including oxidation, deamidation, N-terminal PyroGlu addition, and C-terminal Lys clipping, were compared. The SPR technique was used to reveal antigen and some receptor binding kinetics of all products, and the ELISA technique was used for C1q binding affinity analysis. Finally, the inhibition performance of the samples was evaluated by an MTS-based proliferation assay in vitro. Major glycoforms were similar, with minor differences among the samples. Posttranslational modifications, except C-terminal Lys, were determined similarly, while unclipped Lys percentage was higher in Zirabev. The binding kinetics for VEGF, FcRn, FcγRIa, and C1q were similar or in the value range of originators. The anti-proliferative effect of Zirabev was slightly higher than the originators and Mvasi. The analysis of biosimilars under the same conditions could provide a new aspect to the literature in terms of the applied analytical techniques. Further studies in this field would be helpful to better understand the inter-comparability of the biosimilars.